The company was founded by Min-Han Tan, Pan Zhao, and Yukti Choudhury in 2016. To date, the company has raised approximately $29.2 million, most recently raising a $20 million Series A round in 2019 led by IHH Healthcare. Among its investors, we emphasize IHH Healthcare, Heliconia Capital Management...

This item has been archived in line with our efforts to keep our content relevant and up to date for our readership. For further assistance, please contact your Customer Success Manager or email Thank you!

Related Research

China approves OrgiMed's NGS-based genomic alteration tumor test

News Commentary | September 08, 2021

The test, which was made in collaboration with Bayer, was developed to detect rare NTRK gene fusions in both children and adults. It is a companion diagnostic to a gene inhibitor therapy that specifically targets NTRK cancers. Clients should note how genomic sequencing can be utilized for diagnostic... Not part of subscription

23andMe expands portfolio of approved cancer screenings with latest FDA approval

News Commentary | January 13, 2022

The U.S. FDA has given 23andMe approval to expand its genetic health risk report by screening for a G84E mutation in the HOXB13 gene. This mutation has been linked to an increase in prostate cancer. A recent study showed that males with a G84E gene mutation were 66% more likely to have prostate ... To read more, click here.

NovogeneAIT Genomics

Company Profile | April 29, 2022

NGS vendor providing high‑throughput genome sequencing services in a College of American Pathologists (CAP)‑certified laboratory and liquid biopsy‑based cancer diagnostics Core differentiation lies in having access to a strong IP portfolio in NGS processes and analyses and providing services in... Not part of subscription